$IREN Ltd(IREN)$   IREN Limited (NASDAQ: IREN) is experiencing massive momentum, closing up at $56.56 following a string of transformational AI megadeals. Following the company's Q3 earnings report, Bernstein reiterated an Outperform rating and a $100 price target, implying roughly 76% upside from early-May baseline levels. The Case for Bernstein's $100 Target: Full Pivot to AI Cloud Massive NVIDIA Deal: IREN secured a massive $3.4 billion AI cloud contract with NVIDIA, which also includes a $2.1 billion equity investment option. Hyper-Scale Revenue: The company has contracted 150,000 GPUs, with half already dedicated to a massive five-year agreement with Microsoft generating over $1.94 billion in annualized revenue. Dumping Bitcoin Min

$NIO Inc. USD OV(NIO.SI)$  $XPeng Inc.(XPEV)$   Singapore’s Category A COE is nearing the $125,000 milestone after closing at $124,790 in the latest May 2026 bidding exercise. With the upcoming The Car Expo keeping automotive demand high, mass-market buyers are being heavily squeezed. This raises a major question for automotive stocks: are global automakers in Singapore for massive profit margins, or strictly for brand prestige? The Financial Disconnect: Prestige vs. Real Profits Prestige Play: Singapore serves as a premier showcase market for Southeast Asian luxury branding. Margin Compression: Massive COE taxes heavily inflate retail costs without adding to factory profit margins.

$Rocket Lab USA, Inc.(RKLB)$  $AST SpaceMobile, Inc.(ASTS)$  #RKLB # ASTS  The space sector is seeing a massive divergence today as Rocket Lab ($RKLB) hits all-time highs while AST SpaceMobile ($ASTS) faces a sharp pullback. Is this a rotation into "proven execution" or a classic "buy the dip" opportunity for the satellite leader?🚀 Rocket Lab ($RKLB): The Execution Machine$RKLB is on a tear, surging over 11% today to cross the $117 mark after a "wow" earnings report.Record Numbers: Reported record Q1 revenue of $200.3M (up 64% YoY) and a massive $2.2B backlog.Profitability Pivot: Management stunned Wall Street by guiding for positive adjusted EBITDA of $23M next quarter—a year ahead o

$Lumentum(LITE)$  #Lumentum  Big move for $LITE! Effective prior to market open on May 18, 2026, Lumentum will officially join the Nasdaq-100 Index, replacing CoStar Group.This marks a massive year for the photonics leader—it just joined the S&P 500 in March—and the stock is already up over 145% year-to-date.🌪️ The "Passive Inflow" ThesisForced Buying: Passive funds and ETFs tracking the Nasdaq-100 (which manage over $600 billion) are now required to buy Lumentum shares.The AI Tailwinds: As a key supplier for 800G optical modules, Lumentum is essential to the "physical layer" of AI data centers.Price Targets: Major institutions like Citigroup and Jefferies have recently hiked targets to as high as $1,100 - $1,200.⚠️ The "Take Profit

Tencent just dropped its Q4 2025 results, posting a revenue of RMB 194.4 billion (up 13% YoY) and a net profit of RMB 58.26 billion. While the numbers beat expectations, the real buzz is around WeChat's AI-driven evolution.🚀 The AI "Monetization Point" is HereManagement's commentary suggests AI has shifted from a "research cost" to a "revenue engine" within the WeChat ecosystem:Ad Targeting Supercharge: Marketing services revenue grew 17% to RMB 41.1 billion, largely credited to AI-powered targeting. By better matching ads to user intent, Tencent is squeezing more value out of its existing ad load.The "ClawBot" Integration: Tencent is aggressively rolling out AI agents (like ClawBot) directly into WeChat. These agents aren't just for chat—they are being designed to handle multi-step tasks

The market is opening the week on a high note after the S&P 500 ($7,398.93) and NASDAQ ($26,247.08) both hit fresh record highs on Friday. However, caution is creeping in this morning as futures trade slightly lower ahead of tomorrow's critical April CPI release, with investors bracing for a potential 3.7% year-over-year headline inflation figure.🔥 Top Stocks in Focus TodayTickerCatalystWhat to WatchNVDA (Nvidia)AI Capex BoomAnalysts at Goldman Sachs see multiple catalysts ahead of its earnings call later this month; big tech AI spending is projected to hit $725 billion this year.AMAT (Applied Materials)Earnings (Thurs)Reporting later this week; options are pricing in a volatile +/- 8.7% move. The stock is already up ~12% so far in May.BABA (Alibaba)China Tech SentimentReporting Wednes

$AST SpaceMobile, Inc.(ASTS)$  The space race is heating up, and investors are comparing the "execution king" Rocket Lab ($RKLB) with the "high-reward disruptor" AST SpaceMobile ($ASTS). With both companies reporting, here is the quick breakdown of the 2026 momentum:Rocket Lab ($RKLB): The Execution Leader.Commercial Win: Just reported record Q1 2026 revenue of $200.3 million (up 63.5% YoY).Backlog: Their massive $2.2 billion backlog proves they have steady, real-world demand from both government and commercial customers.Status: Moving toward profitability with a diversified business (launches + satellite parts).AST SpaceMobile ($ASTS): The High-Growth Wildcard.Commercial Pivot: Reported $70.9 million in 2025 revenue—a huge jump from their "p

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

w

Great analysis. It’s wild to see an 11% drop despite record revenue ($808.4M) and a massive operating margin expansion. With the $2 billion Nvidia investment now on the balance sheet, this feels more like a technical 'buy the news' pullback than a change in the AI narrative. I’m viewing this dip as a solid entry point for the long term

W

I am grateful for the current stock market situation as amidst the bleak looking market situation it is actually a chance for long term investor to havea chance to achieve generational wealth during this period

To allow commission free trades without any referral being done this is so done so that more investors would be enticed by tiger'a perks being given and hence attract even more investors to comeabroad tiger or from other brokerages.